Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1409 | Environmental exposure and clinical features Wiki | 1.00 |
| drug3399 | Routine care for COVID-19 patients Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Plasma therapy using convalescent plasma has been shown to be effective in severe acute respiratory syndrome, Ebola virus infection and in H1N1 influenza. More recently there has been a report of the use of convalescent plasma in the treatment of 5 ventilated COVID-19 patients with the suggestion of expedited recovery as the patients improved 1 week after the transfusion. However, this was not a clinical trial and the patients were on other antiviral medication.; therefore, there is a need to undertake such a trial to see if deploying plasma with SARS-CoV-2 neutralizing antibody has utility in managing patients infected with COVID-19 in respiratory distress. The objective of this pilot study is to compare plasma therapy using convalescent plasma with antibody against SARS-CoV-2 to usual supportive therapy in COVID-19 patients with pneumonia and hypoxia, and to determine if the clinical course is improved. The difference between groups will allow an effect size to be determined for a definitive clinical trial.
Description: Could the plasma therapy avoid or delay the need for invasive ventilation
Measure: Requirement for invasive ventilation Time: through study completion up to 28 daysDescription: Through the use of CT values
Measure: Change in viral clearance Time: through study completion up to 28 daysDescription: Chest Xray
Measure: Radiological change Time: through study completion up to 28 daysDescription: As a measure of a change in inflammation
Measure: Change in white cell count Time: through study completion up to 28 daysDescription: A change in C reactive protein as a measure of a change in inflammation
Measure: C reactive protein measurement Time: through study completion up to 28 daysDescription: A change in lactate dehydrogenase as a measure of an improvement in the severity of the disease process
Measure: lactate dehydrogenase measurement Time: through study completion up to 28 daysDescription: A change in procalcitonin as a measure of an improvement in the severity of the disease process
Measure: Procalcitonin measurement Time: through study completion up to 28 daysDescription: A change in D Dimer as a measure of an improvement in the severity of the disease process
Measure: D Dimer measurement Time: through study completion up to 28 daysDescription: A change in Ferritin as a measure of an improvement in the severity of the disease process
Measure: Ferritin measurement Time: through study completion up to 28 daysDescription: A change in troponin T as a measure of an improvement in the severity of the disease process
Measure: Troponin T measurement Time: through study completion up to 28 daysDescription: A change in brain naturetic peptide as a measure of an improvement in the severity of the disease process
Measure: Brain naturetic peptide measurement Time: through study completion up to 28 daysDescription: Mortality rate due to COVID-19
Measure: Mortality rate Time: Up to 28 days of the studyAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports